title: Alefacept (anti-CD2) causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.
abstract: BACKGROUND
  Alefacept (anti-CD2) biological therapy selectively targets effector memory T cells (Tem) in psoriasis vulgaris, a model Type 1 autoimmune disease.
  
  
  METHODS
  Circulating leukocytes were phenotyped in patients receiving alefacept for moderate to severe psoriasis.
  
  
  RESULTS
  In all patients, this treatment caused a preferential decrease in effector memory T cells (CCR7- CD45RA-) (mean 63% reduction) for both CD4+ and CD8+ Tem, while central memory T cells (Tcm) (CCR7+CD45RA-) were less affected, and naïve T cells (CCR7+CD45RA+) were relatively spared. Circulating CD8+ effector T cells and Type 1 T cells (IFN-gamma-producing) were also significantly reduced.
  
  
  CONCLUSIONS
  Alefacept causes a selective reduction in circulating effector memory T cells (Tem) and relative preservation of central memory T cells (Tcm) in psoriasis.
authors.affiliation: Laboratory for Investigative Dermatology, The Rockefeller University, New York, USA. mfnchamian@msn.com
authors.forename: Francesca
authors.initials: F
authors.lastname: Chamian
authors.forename: Shao-Lee
authors.initials: SL
authors.lastname: Lin
authors.forename: Edmund
authors.initials: E
authors.lastname: Lee
authors.forename: Toyoko
authors.initials: T
authors.lastname: Kikuchi
authors.forename: Patricia
authors.initials: P
authors.lastname: Gilleaudeau
authors.forename: Mary
authors.initials: M
authors.lastname: Sullivan-Whalen
authors.forename: Irma
authors.initials: I
authors.lastname: Cardinale
authors.forename: Artemis
authors.initials: A
authors.lastname: Khatcherian
authors.forename: Inna
authors.initials: I
authors.lastname: Novitskaya
authors.forename: Knut M
authors.initials: KM
authors.lastname: Wittkowski
authors.forename: James G
authors.initials: JG
authors.lastname: Krueger
authors.forename: Michelle A
authors.initials: MA
authors.lastname: Lowes
mesh_terms: D000328:Adult; D000368:Aged; D000077944:Alefacept; D015703:Antigens, CD / Q000276:immunology; D000945:Antigens, Differentiation, T-Lymphocyte / Q000276:immunology; D018801:CD2 Antigens / Q000276:immunology*; D002465:Cell Movement / Q000187:drug effects; D003879:Dermatologic Agents / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006801:Humans; D007156:Immunologic Memory / Q000187:drug effects; D037181:Lectins, C-Type; D008213:Lymphocyte Activation / Q000187:drug effects / Q000276:immunology; D018655:Lymphocyte Count; D016131:Lymphocyte Subsets / Q000187:drug effects / Q000473:pathology; D008297:Male; D008875:Middle Aged; D010641:Phenotype; D011565:Psoriasis / Q000188:drug therapy* / Q000276:immunology* / Q000473:pathology; D011993:Recombinant Fusion Proteins / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use*; D013601:T-Lymphocytes / Q000187:drug effects / Q000276:immunology* / Q000473:pathology; D000099192:CD69 Antigens
chemical_list: D000077944:Alefacept; D015703:Antigens, CD; D000945:Antigens, Differentiation, T-Lymphocyte; D018801:CD2 Antigens; D003879:Dermatologic Agents; D037181:Lectins, C-Type; D011993:Recombinant Fusion Proteins; D000099192:CD69 Antigens